Prescription weight loss medications are FDA-approved drugs categorized by mechanism, including orlistat (lipase inhibitor), phentermine-topiramate and naltrexone-bupropion (centrally acting agents), and GLP-1 receptor agonists like liraglutide, semaglutide, and tirzepatide. The FDA has approved six drugs for long-term chronic weight management, with setmelanotide reserved for rare genetic obesity. Understanding the types of weight loss prescriptions available helps you match the right medication to your health profile, not just your weight. Each drug class works differently, carries distinct side effects, and comes with specific eligibility requirements. Medical supervision is required across all categories because side effects can be severe and these medications function as adjuncts to lifestyle change, not replacements for it.
1. Types of weight loss prescriptions available: an overview
The prescription weight loss medication categories recognized by the FDA fall into four main groups: lipase inhibitors, centrally acting agents, incretin mimetics, and genetic obesity treatments. Each group targets a different biological pathway. Lipase inhibitors block fat digestion in the gut. Centrally acting agents suppress appetite through brain chemistry. Incretin mimetics regulate hunger hormones and slow gastric emptying. Genetic obesity treatments address specific gene mutations that cause severe early-onset obesity.
Eligibility for most of these medications requires a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, high blood pressure, or obstructive sleep apnea. Some medications are approved for adolescents aged 12 and older. The right choice depends on your comorbidities, cost tolerance, preferred dosing format, and how your body responds to treatment.
2. Orlistat: the lipase inhibitor option
Orlistat is the only FDA-approved lipase inhibitor for weight loss, and it works by blocking roughly one-third of the fat you consume from being absorbed in the gut. That unabsorbed fat passes through the digestive system, which is both the mechanism and the source of its most common side effects. Orlistat is sold as Xenical at prescription strength (120 mg) and as Alli over the counter at a lower dose (60 mg).
Common side effects include:
- Oily or fatty stools
- Frequent or urgent bowel movements
- Oily spotting on underwear
- Flatulence with discharge
- Reduced absorption of fat-soluble vitamins A, D, E, and K
Because orlistat reduces fat-soluble vitamin absorption, a daily multivitamin taken at least two hours before or after the dose is standard practice. Orlistat is considered the least potent option among FDA-approved weight loss drugs, but it carries no cardiovascular or psychiatric risks, making it a reasonable choice for patients who cannot tolerate other medications.
Pro Tip: Take orlistat with meals containing no more than 30% of calories from fat. Higher fat meals significantly worsen gastrointestinal side effects and make adherence much harder.
3. Phentermine-topiramate and naltrexone-bupropion: centrally acting agents
Centrally acting agents reduce appetite and food intake by targeting neurotransmitter systems in the brain. Two combination drugs dominate this category: phentermine-topiramate (brand name Qsymia) and naltrexone-bupropion (brand name Contrave). Both are oral pills that affect hunger control through different neurochemical pathways.
Phentermine-topiramate (Qsymia):
- Once-daily pill combining a stimulant (phentermine) with an anticonvulsant (topiramate)
- Phentermine suppresses appetite; topiramate reduces food cravings and promotes satiety
- Not recommended during pregnancy due to risk of birth defects from topiramate
- Contraindicated in patients with hyperthyroidism, glaucoma, or recent MAOI use
- Approved for adults and adolescents aged 12 and older
Naltrexone-bupropion (Contrave):
- One to two doses daily combining an opioid antagonist (naltrexone) with an antidepressant (bupropion)
- Targets the hypothalamus and reward pathways to reduce hunger and food cravings
- Contraindicated in patients with seizure disorders, eating disorders, or those using opioids
- Carries an FDA black box warning for increased suicidal thoughts, consistent with other bupropion products
- Approved for adults only
Both drugs require gradual dose titration over several weeks to minimize side effects including nausea, insomnia, dry mouth, and elevated heart rate. Neither is appropriate for patients with uncontrolled hypertension. Your prescriber will review your full medication list before starting either drug because interactions are clinically significant.
4. GLP-1 receptor agonists: the most effective weight loss prescriptions
GLP-1 receptor agonists and the dual GIP/GLP-1 agonist tirzepatide represent the most effective prescription weight loss medication category currently available. These incretin mimetics work by mimicking gut hormones that signal fullness to the brain, suppress appetite, and slow gastric emptying. The result is reduced caloric intake without the stimulant effects of centrally acting agents.
The three key drugs in this class are:
- Liraglutide (Saxenda): Daily subcutaneous injection, approved for adults and adolescents 12 and older with obesity
- Semaglutide (Wegovy): Weekly subcutaneous injection, also available as a daily oral tablet (Rybelsus, though primarily approved for type 2 diabetes)
- Tirzepatide (Zepbound): Weekly subcutaneous injection, targets both GLP-1 and GIP receptors for additive appetite suppression
Tirzepatide achieves greater than 20% body weight reduction in some patients, which is a result that surpasses every other FDA-approved weight loss drug. That level of weight loss was previously achievable only through bariatric surgery. Semaglutide produces approximately 15% average weight loss in clinical trials, and liraglutide produces around 5 to 8%.
Side effects across this class are primarily gastrointestinal: nausea, vomiting, diarrhea, and constipation, especially during dose escalation. These effects typically diminish after the first few weeks. For a deeper look at how these medications work at the receptor level, the GLP-1 mechanism explained by Daylahealth covers benefits and side effects in detail. Rare but serious risks include pancreatitis and a theoretical risk of thyroid C-cell tumors based on animal studies, which is why these drugs carry a black box warning for patients with a personal or family history of medullary thyroid carcinoma.
5. Setmelanotide: prescription treatment for genetic obesity
Setmelanotide (brand name IMCIVREE) is an entirely different category of weight loss prescription. It is approved only for patients with rare genetic obesity disorders confirmed by genetic testing, specifically deficiencies in POMC, PCSK1, LEPR, or related genes in the melanocortin-4 receptor pathway.
Key features of setmelanotide include:
- Administered as a daily subcutaneous injection
- Targets the MC4R pathway in the hypothalamus to restore impaired hunger signaling
- Eligibility requires genetic confirmation, not BMI criteria alone
- Approved for patients aged 6 years and older with qualifying genetic mutations
- Not appropriate for common obesity or lifestyle-related weight gain
This drug does not belong in the same conversation as Wegovy or Zepbound for most people. Its patient population is small and highly specific. Side effects include injection site reactions, skin hyperpigmentation, nausea, and spontaneous penile erections in male patients. If you have a history of severe early-onset obesity with hyperphagia that has not responded to standard treatments, genetic testing through an endocrinologist is the appropriate first step.
6. How these weight loss prescriptions compare
Choosing among prescription diet pills and injectable medications requires weighing effectiveness, side effects, dosing format, and cost against your personal health profile. The table below summarizes the key differences.
| Drug (Brand) | Class | Avg. Weight Loss | Dosing | Common Side Effects | Min. Eligibility |
|---|---|---|---|---|---|
| Orlistat (Xenical) | Lipase inhibitor | 3 to 5% | Oral, 3x daily with meals | Oily stools, GI urgency | BMI 30+ (or 27+ with condition) |
| Phentermine-topiramate (Qsymia) | Centrally acting | 8 to 10% | Oral, once daily | Dry mouth, insomnia, elevated HR | BMI 30+ (or 27+ with condition) |
| Naltrexone-bupropion (Contrave) | Centrally acting | 5 to 8% | Oral, 1 to 2x daily | Nausea, headache, insomnia | BMI 30+ (or 27+ with condition) |
| Liraglutide (Saxenda) | GLP-1 agonist | 5 to 8% | Daily injection | Nausea, vomiting, diarrhea | BMI 30+ (or 27+ with condition) |
| Semaglutide (Wegovy) | GLP-1 agonist | ~15% | Weekly injection | Nausea, constipation, fatigue | BMI 30+ (or 27+ with condition) |
| Tirzepatide (Zepbound) | Dual GIP/GLP-1 | 20%+ | Weekly injection | Nausea, vomiting, diarrhea | BMI 30+ (or 27+ with condition) |
| Setmelanotide (IMCIVREE) | MC4R agonist | Varies | Daily injection | Skin pigmentation, nausea | Genetic confirmation required |
Cost and insurance coverage are real barriers. Incretin mimetics like tirzepatide show the best outcomes but carry the highest list prices, often exceeding $1,000 per month without coverage. Orlistat and the oral combination pills are generally more affordable and more widely covered. For a side-by-side breakdown of the two leading injectables, this semaglutide vs tirzepatide comparison provides detailed research data.
Obesity pharmacotherapy is long-term chronic care, not a short course. Expert guidance from the Obesity Society supports continuing medications during weight maintenance phases, not stopping once a target weight is reached. Periodic clinical reassessments determine whether to continue, adjust, or switch medications based on ongoing benefit and tolerability.
Pro Tip: Match your medication to your comorbidities. Patients with type 2 diabetes benefit most from GLP-1 agonists, which also improve blood sugar control. Patients with a history of depression or seizures should avoid naltrexone-bupropion and phentermine-topiramate respectively.
Key takeaways
Prescription weight loss medications fall into four distinct categories, and the most effective option for you depends on your health profile, not just your BMI.
| Point | Details |
|---|---|
| Four drug categories exist | Lipase inhibitors, centrally acting agents, incretin mimetics, and genetic obesity treatments each work differently. |
| GLP-1 agonists lead in effectiveness | Tirzepatide achieves over 20% weight loss in some patients, the highest of any FDA-approved drug. |
| Eligibility is BMI-based for most | A BMI of 30 or higher, or 27 with a comorbidity, qualifies most adults for prescription weight loss drugs. |
| Cost shapes real-world access | Insurance barriers and high list prices for injectables often determine which medication patients actually use. |
| Treatment is long-term | Expert consensus supports continuing medications during weight maintenance, not stopping after initial weight loss. |
What I've learned about matching patients to the right weight loss prescription
Selecting a weight loss prescription is a matching process, not a ranking exercise. The most effective drug on paper is not always the right drug for the person in front of you. I have seen patients who qualify for tirzepatide on paper but cannot afford it without insurance coverage, and patients who do well on naltrexone-bupropion because it also addresses their food reward patterns. Drug selection should be individualized based on comorbidities, cost, and patient preference, and that principle holds up in practice every time.
The biggest misconception I encounter is that weight loss medications are a short-term fix. They are not. The evidence for long-term use is strong, and stopping medication after reaching a goal weight typically leads to weight regain within months. Patients need to understand this before they start, not after they plateau.
Side effect concerns are legitimate but often manageable. Nausea from GLP-1 agonists peaks in the first four to eight weeks and resolves for most patients who titrate slowly. Gastrointestinal issues with orlistat are almost entirely diet-dependent. The patients who struggle most are those who were not counseled on what to expect before their first dose. Preparation matters more than the drug itself in the early weeks.
Cost and insurance access remain the most frustrating barriers in this space. Tirzepatide's results are genuinely impressive, but a medication that costs over $1,000 per month out of pocket is not accessible for most Americans. Until coverage improves, prescribers and patients have to make decisions based on what is actually affordable and sustainable, not just what performs best in trials. That reality shapes every treatment conversation worth having.
— Flexible
Start your personalized weight loss plan with Daylahealth
Daylahealth offers doctor-led access to GLP-1 weight loss prescriptions including semaglutide and liraglutide, with personalized care built around your health profile and goals.
You do not need to sort through drug categories on your own. Daylahealth connects you with licensed clinicians who review your eligibility, explain your options, and monitor your progress. The intake process is straightforward, and medical guidance is built into every step. If you are ready to explore GLP-1 weight loss options with clinical support behind you, Daylahealth makes that access direct and medically sound. You can also use the weight loss program checklist to compare your options before your first consultation.
FAQ
What are the main types of weight loss prescriptions?
The FDA has approved drugs across four categories: lipase inhibitors (orlistat), centrally acting agents (phentermine-topiramate, naltrexone-bupropion), incretin mimetics (liraglutide, semaglutide, tirzepatide), and genetic obesity treatments (setmelanotide). Each works through a different biological mechanism and carries distinct eligibility requirements.
Which weight loss prescription is the most effective?
Tirzepatide (Zepbound) produces the greatest weight loss of any FDA-approved drug, with some patients achieving over 20% body weight reduction. Semaglutide (Wegovy) follows at approximately 15% average weight loss in clinical trials.
Who qualifies for prescription weight loss medications?
Most FDA-approved weight loss drugs require a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes or high blood pressure. Setmelanotide requires genetic confirmation of a qualifying mutation rather than BMI criteria.
Why do weight loss drugs require a prescription?
Prescription weight loss medications require medical supervision because side effects can be serious, interactions with other drugs are common, and these medications are intended as part of a broader chronic disease management plan, not cosmetic tools. A clinician must assess your full health history before prescribing.
How long do you stay on weight loss prescriptions?
Weight loss medications are designed for long-term use. Expert guidance from the Obesity Society supports continuing treatment during weight maintenance phases, with periodic reassessments to confirm ongoing benefit and tolerability rather than stopping at a fixed endpoint.